The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Germany says AstraZeneca lawsuit "not priority" for now

Fri, 23rd Apr 2021 12:53

(Alliance News) - Germany would support legal action against AstraZeneca PLC for under-delivering Covid-19 vaccine doses to the EU, but the priority now should be on securing the jabs, Health Minister Jens Spahn said Friday.

The European Commission is considering a lawsuit against the Swedish-British pharmaceutical giant for so far delivering just 31 million of the 120 million doses it had promised, according to EU diplomats.

Asked if he thought the lawsuit was a good idea, Spahn said: "If (the commission) decides to take legal action, then yes... but it's much more important to me that I get this vaccine."

Germany wants to "cooperate with AstraZeneca to get as many deliveries as possible as quickly as possible", he said, adding that legal issues are "not yet a priority in this phase of the pandemic".

EU diplomats said Thursday no final decision has been taken on legal action but the EU executive has informed member state envoys and wants them to confirm whether they would back a lawsuit.

"As you know, AstraZeneca is not delivering the number of doses which have been agreed upon in the contract... This is one of the reasons why we keep our options open together with member states to take any further steps," commission spokesman Stefan De Keersmaecker said on Thursday.

One diplomat told AFP that "not all member states are in agreement" on taking the company to court, stressing that their aim was simply to have AstraZeneca deliver the doses it had promised in its contract.

Public confidence in the AstraZeneca jab has taken a blow after the European Medicines Agency, the bloc's regulator, said it was likely linked to a very rare form of blood clot affecting the brain. 

The EMA and the commission have not changed their stance on a general use of AstraZeneca, saying its benefits outweigh the risks, but several EU countries have restricted its use to older citizens.

The EU, however, is now increasingly relying on the BioNTech SE/Pfizer Inc vaccine for its rollout, which has been accelerating since the end of March.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group s...

21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in Lond...

21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings *

21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the B...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.